Research & Development

Lantheus to acquire oncology company Progenics Pharmaceuticals

Lantheus Holdings has signed an agreement to acquire oncology company Progenics Pharmaceuticals in an all-stock transaction.

Sobi to buy Dova Pharmaceuticals in $915m deal

Swedish Orphan Biovitrum (Sobi) has agreed to acquire Dova Pharmaceuticals in a deal valued at around $915m.

Blade Therapeutics expands anti-fibrotic pipeline with acquisition of ATXCo and its autotaxin inhibitor

Blade Therapeutics, a biopharmaceutical company advancing novel anti-fibrotic therapies, today announced the acquisition of ATXCo, Inc., including its core asset, PAT-409, a Phase I ready autotaxin inhibitor for patients with fibrotic diseases.

Amphivena closes $62m Series C financing to expand clinical development of AMV564 into solid tumors and to develop T Cell engagement portfolio

Amphivena Therapeutics, Inc., a private clinical stage immuno-oncology company developing T cell engager therapeutics for cancer, announced today the closing of a $62 million Series C financing.

Pfizer expands real-world data collaboration with Flatiron Health

Pfizer has expanded its collaboration with oncology software provider Flatiron Health to integrate and increase the application of real-world data further in its development of targeted cancer drugs.

Boehringer Ingelheim signs retinal disease deal with Inflammasome

Boehringer Ingelheim has forged a co-development and license agreement worth $160m (£128.8m) with science-based company Inflammasome Therapeutics to develop up to three new therapies for retinal diseases.

Ironwood Pharmaceuticals and AstraZeneca amend LINZESS (linaclotide) collaboration in China

Ironwood Pharmaceuticals, a GI healthcare company, announced today that it has amended its collaboration agreement with AstraZeneca for the development and commercialization of LINZESS in China.

Accenture announces collaboration with Bayer to streamline drug development processes through INTIENT clinical platform

Accenture has announced a collaboration with Bayer to implement the Accenture INTIENT Clinical platform to help simplify and speed its drug development processes.

Lundbeck to buy Alder BioPharmaceuticals for £1.56bn

Lundbeck has agreed to acquire clinical-stage biopharmaceutical company Alder BioPharmaceuticals in a deal valued at around $1.95bn (£1.56bn).